Now ideas for wellness

About Meiji

At a Glance

At a Glance

Get to know Meiji at a glance – from our core business to our most important numbers.

Infectious Diseases

an image of bacteria that cause infections

The fight against infectious diseases has been one of Meiji's major social contributions, from our early manufacture of penicillin drugs beginning in 1946 to the development of the world's first and only oral carbapenem antibiotic. We also produce generic antibacterial agents for systemic use, while our vaccine products allow us to prevent infectious diseases, not only treat them.

  • a photo of people experimenting in the lab.
  • Infectious Disease Control is a National Security Issue

    The stable supply of antimicrobial agents is a national security issue, as manufacturing delays overseas can quickly impact on domestic medical care. Ten antibacterial drugs have been specified by academic societies as clinically important "Key Drugs" in Japan. Meiji has a large market share for several of these key drugs and is looking at ways to strengthen its supply chains to reduce any risks to the general population.

  • Meiact: A Leading Global Antibiotic

    Meiact, an antibiotic drug first approved in Japan in 1994, has become widely prescribed globally. Later clinical trial data compiled by Meiji Seika Pharma found Meiact to be effective against newly resistant bacteria, which attracted a great deal of attention at the time. Meiact has a reputation for safety, which has made it a popular prescription for children. It is now approved for use in many parts of the world including Europe and Asia. 

  • a photo of Meiact packages sold in five countries around the world.
  • Find out more from our wellness stories

    an image of bacteria that cause infections

    The Hidden Health Crisis of AMR

    Meiji is tackling a health crisis the pharmaceutical industry has largely ignored: the spread of antibiotic-resistant bacteria.

    READ MORE